CHIME Pan-cancer: development and validation of AI-based models for cancer precision pathology in populations representative studies

Cancer is a leading cause of death globally.

Precision medicine, offering novel (targeted) therapies, has the potential to substantially improve cancer patient outcomes.

However, to be effective, precision diagnostic solutions for patient stratification (prognostic and predictive) are required.

To improve outcomes for broad groups of patients, fast, reliable and cost-effective precision diagnostic solutions are needed. Current routine diagnosis of cancer is based on manual histopathological assessment, which is imprecise.

Molecular diagnostics offers improved patient stratification, but at a high price, limiting patient access and imposing a high economic burden on healthcare systems.

CHIME develops, validates and contributes to translation of AI-based image analysis solutions (computational pathology) for cancer diagnosis and patient stratification that meet current and future needs in clinical cancer precision medicine, trials and cancer research.

Clinical pathology is undergoing a digital transition that enables translation of AI-based decision support tools for precision diagnostics at a fraction of the cost of molecular diagnostics.

CHIME will leverage large and unique study materials (>400,000 histopathology images and clinical data with outcomes) for the development and validation of clinically relevant models for patient stratification in multiple cancer diseases. CHIME will contribute toward increased access to precision diagnostic and equality in cancer care.